Role of neutrophil to lymphocyte ratio in risk stratifying patients with unstable angina and N-STEMI

Abstract

cute coronary syndrome (ACS) is the leading cause of death worldwide. ACS covers a wide spectrum of clinical conditions, ranging from unstable angina pectoris (UAP) to non-ST elevation myocardial infarction (N-STEMI) or ST elevation myocardial infarction (STEMI). UAP and NSTEMI are closely related conditions, with similar pathophysiological origins and clinical presentations, but they differ in severity. In a patient experiencing UAP, no biomarker can be detected in the bloodstream hours after the initial onset of ischemic chest pain. Early effective risk stratification is essential for the management of patients with acute coronary syndrome. Unlike patients with ST-elevation myocardial infarction (STEMI), Patients with non-STEMI have a different time limitation in performing intervention. So, in a treatment of non-STEMI patients, early prediction of prognosis makes decisions regarding pharmacologic and interventional treatments, allocation of clinical resources, and triage among alternative levels of hospital care.